Recombinated human ctla4ig fusion protein had been used experimentally and clinically in prevention and treatment of transplant rejection , autoimmune diseases and allergic diseases , and positive curiative results were obtained 重组人ctla4ig融合蛋白已被运用于防治移植排斥反应、自身免疫性疾病和变应性疾病等的实验和临床研究，并取得了肯定的效果。
But the systedric bounosuppressive agents , which are obviously a double - bladed sword , have a lot of side effects and toxicities , which have formed hapetus to seek methods and strategies for induction of donor - specilic tolerance 树突状细胞( dendritic cells , dc )作为一类具有最强抗原提呈功能的细胞群体，在识别和提呈抗原启动免疫应答、诱导移植排斥中起重要的作用。
Hence , yeast gs115 was used to express the target protein in this study . objection : to obtain the biological activated recombianated protein of huaman ctla4 extracellular domain ( ctla4e ) , and to explore its effects on allergic diseases and transplant rejection 目的：获取具有生物学活性的重组人ctla4胞外区蛋白（ ctla4e ） ，探讨其在变应性疾病和器官移植排斥反应防治中的作用和机理。
Although the development of relatively non - toxic immunosuppressive or tolerance - inducing regimens will be required to justify clinical trials using pig organs , recent advances in our understanding of the biology of xenograft rejection and zoonotic infections , and the generation of alpha1 , 3 - galactosyltransferase - deficient pigs have moved this approach closer to clinical application 尽管用猪的器官进行临床试验尚有赖于相对无毒的免疫抑制剂或致耐方法的发展，但是我们在异种移植排斥反应及猪源人畜共患病等方面生物学知识的进步，以及1 ， 3半乳糖转移酶缺陷猪的产生，已经使异种移植离临床应用更近了一步。
Although the deelopment of relatiely non - toxic immunosuppressie or tolerance - inducing regimens will be required to justify clinical trials using pig organs , recent adances in our understanding of the biology of xenograft rejection and zoonotic infections , and the generation of alpha1 , 3 - galactosyltransferase - deficient pigs hae moed this approach closer to clinical application 尽管用猪的器官去验证临床试验需要相对无毒的免疫抑制剂或致耐的方法，但随着近来我们对异种移植排斥生物学及动物传染病感染的深入理解，以及1 ， 3半乳糖转移酶缺陷猪的产生，异种移植更接近临床应用。
